

Pharmaceutical Benefits Scheme (PBS) Listings

1 October 2025

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 October 2025**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Severe active rheumatoid arthritis; severe psoriatic arthritis; severe chronic plaque psoriasis; ankylosing spondylitis; severe active juvenile idiopathic arthritis

Etanercept (50 mg/mL injection, 4 x 1 mL pen devices; 50 mg/mL injection, 4 x 1 mL syringes) (Erelzi®) is a new biosimilar now listed on the PBS for the treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, severe chronic plaque psoriasis, ankylosing spondylitis and severe active juvenile idiopathic arthritis.

Primary hyperoxaluria type 1

Lumasiran (94.5 mg/0.5 mL injection, 0.5 mL vial) (Oxlumo®) is now listed on the PBS for the treatment of primary hyperoxaluria type 1. Authority applications for initial, grandfather and continuing treatments can be made using the Online PBS Authorities system or in writing.

Proliferative diabetic retinopathy (PDR) and/or Diabetic macular oedema (DMO)

Ranibizumab (1.65 mg/0.165 mL injection, 0.165 mL syringe; 2.3 mg/0.23 mL injection, 0.23 mL vial) (Lucentis®) has had a change to the existing listing. It is now listed for the treatment of PDR and/or DMO. Authority applications for initial treatment can be made either in real-time using the Online PBS Authorities system or by telephone. Prescriptions for continuing treatment are Authority required (STREAMLINED).

Locally advanced or metastatic breast cancer

Capivasertib (160 mg tablet; 200 mg tablet) (Truqap®) is now listed on the PBS for the treatment of locally advanced or metastatic breast cancer. Authority applications can be made either in real-time using the Online PBS Authorities system or by telephone.

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Dabrafenib (50 mg capsule; 75 mg capsule) (Tafinlar®) & trametinib (500 microgram tablet; 2 mg tablet) (Mekinist®) are now listed on the PBS for the treatment of stage IV (metastatic) NSCLC. Prescriptions for each drug are Authority required (STREAMLINED).

Contraception

Estetrol + drospirenone (estetrol 14.2 mg + drospirenone 3 mg tablet [24] (&) inert substance tablet [4], 3 x 28) (Nextstellis®) is now listed on the PBS for contraceptive use. It is listed as an unrestricted benefit.

1 October 2025 delisted PBS listings

Diabetic macular oedema (DMO)

Aflibercept (8 mg/0.07 mL injection, 0.07 mL vial) (Eylea®) no longer has a listing for Grandfather arrangements.

PBS Authorities – Changes from 1 October 2025

We understand having access to PBS-subsidised medicines can be critical to patient care. That's why Services Australia and the Department of Health, Disability and Ageing are continuing to work together to increase the number of PBS medicines that can be requested and approved using the Online PBS Authorities system (the system).

From 1 October 2025, you will be able to use the system to apply for authority approval and provide evidence digitally for the following medicines. These changes will make it easier for you to request authority approval for these medicines from Services Australia. You will no longer need to submit the written authority application form, details of the proposed prescriptions and test results for certain medicines and treatment phases.

Treatment of ankylosing spondylitis

Authority applications for initial, change or recommencement and continuing treatments for patients with adalimumab, bimekizumab, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, secukinumab, tofacitinib and upadacitinib can now be made either using the Online PBS Authorities system or in writing. Authority applications for initial treatment with biosimilar brands can be made either in real-time using the Online PBS Authorities system or by telephone. Prescriptions for continuing treatment with biosimilar brands are Authority required (STREAMLINED).

Important Information

Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit servicesaustralia.gov.au/HPOS for more information on how to Link your Health Identifiers to HPOS and Manage delegations.

PBS Authorities items criteria

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by PBAC, you can contact the Department of Health, Disability and Ageing by email at pbs@health.gov.au.

Reminders

PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval.

Correct PBS item code

When prescribing PBS medicines via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.

Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.

More information

For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.